Assessing the impact of exome sequencing on diagnostic yield in a large cohort of Brazilian patients
Authors:
- Aline Cristiane PlanelloAPAline Cristiane Planello
- Thereza LoureiroTLThereza Loureiro
- Dayse Alencar-CupertinoDADayse Alencar-Cupertino
- Diana BermeoDBDiana Bermeo
- Joselito SobreiraJSJoselito Sobreira
- Mireille GomesMGMireille Gomes
- Luciana Santos Serrao de CastroLCLuciana Santos Serrao de Castro
- Darine VillelaDVDarine Villela
- Cristovam Scapulatempo-NetoCSCristovam Scapulatempo-Neto
- Nara SobreiraNSNara Sobreira
Open Access
- 1 January 2025
- journal article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (7) , e20250086
Abstract
SUMMARY OBJECTIVE: This study aimed to evaluate whether the increased use of exome sequencing as a primary next-generation sequencing test provides a higher diagnostic yield compared to multi-gene panels for various clinical indications within a Brazilian cohort. METHODS: We retrospectively analyzed test results from 3,025 patients who underwent single-gene tests, multi-gene panels, and exome sequencing in our laboratory. The results were categorized as positive, inconclusive, or negative, with clinical indications including neurodevelopmental, late-onset neurological, neuromuscular, syndromic, skin/hair, hematological/immunologic, ophthalmologic, inborn errors of metabolism, skeletal, cardiovascular, reproductive planning, cancer, genitourinary, gastrointestinal, and hearing disorders. RESULTS: Of the 3,025 next-generation sequencing-based tests, 420 were single-gene tests, 1,158 were multi-gene panels, and 1,447 were exome sequencing. Although multi-gene panels were initially the most frequently ordered test, exome sequencing currently represents 62% of all next-generation sequencing-based tests performed in our laboratory. Exome sequencing had the highest detection rate (32.7%), but also the highest inconclusive rate. Among the clinical indications, when stratified by exome sequencing, skeletal and hearing disorders had the highest diagnostic yield, corresponding to 55 and 50%, respectively. CONCLUSION: This study emphasizes the diagnostic usefulness of exome sequencing for complex genetic disorders in postnatal diagnosis. However, the expansion of exome sequencing also presents challenges, including an increased rate of inconclusive results due to variants of uncertain significance. Broader availability of exome sequencing must be accompanied by additional resources to address these challenges effectively.Keywords
This publication has 15 references indexed in Scilit:
- Health equity in the implementation of genomics and precision medicine: A public health imperativeGenetics in Medicine, 2022
- Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2021
- Understanding genetic variants of uncertain significancePaediatrics & Child Health, 2021
- The clinical utility of exome and genome sequencing across clinical indications: a systematic reviewHuman Genetics, 2021
- Personalised virtual gene panels reduce interpretation workload and maintain diagnostic rates of proband-only clinical exome sequencing for rare disordersJournal of Medical Genetics, 2021
- Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersGenetics in Medicine, 2019
- A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurologyGenetics in Medicine, 2017
- Clinical application of whole-exome sequencing across clinical indicationsGenetics in Medicine, 2016
- Brazil's Mixed Public and Private Hospital System.2015
- Molecular Findings Among Patients Referred for Clinical Whole-Exome SequencingJAMA, 2014